These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 999448)

  • 1. Drug refusal in schizophrenia and the wish to be crazy.
    Van Putten T; Crumpton E; Yale C
    Arch Gen Psychiatry; 1976 Dec; 33(12):1443-6. PubMed ID: 999448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
    Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The "ego" structure in paranoid schizophrenia].
    Jakubik A; Budna A; Gapińska E; Lepianka I
    Psychiatr Pol; 1990; 24(4):30-4. PubMed ID: 2131467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Schizophrenia and violence, incidence and risk factors: a Tunisian sample].
    Ellouze F; Ayedi S; Masmoudi S; Bakri L; Chérif W; Zramdini R; Largueche M; Amri H; Ben Abla T; M'rad MF
    Encephale; 2009 Sep; 35(4):347-52. PubMed ID: 19748371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
    Liu-Seifert H; Adams DH; Kinon BJ
    BMC Med; 2005 Dec; 3():21. PubMed ID: 16375765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective response to antipsychotic drugs.
    Van Putten T; May PR; Marder SR; Wittmann LA
    Arch Gen Psychiatry; 1981 Feb; 38(2):187-90. PubMed ID: 7212946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between insight and symptoms in schizophrenia.
    Sevy S; Nathanson K; Visweswaraiah H; Amador X
    Compr Psychiatry; 2004; 45(1):16-9. PubMed ID: 14671732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics of chronic schizophrenic patients presenting with severe anhedonia].
    Loas G; Noisette C; Legrand A; Boyer P; Delahousse J
    Encephale; 1996; 22(5):351-8. PubMed ID: 9035991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Co-enaesthetic schizophrenia. Case studies of illness perception and compliance].
    Schmoll D
    Fortschr Neurol Psychiatr; 1994 Oct; 62(10):372-8. PubMed ID: 8001893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to antipsychotic medication: the doctor's and the consumer's view.
    Van Putten T; May PR; Marder SR
    Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug compliance and health locus of control in schizophrenia].
    Combes C; Feral F
    Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 19. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
    Emsley R; Rabinowitz J; Medori R;
    Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness of illness in schizophrenia.
    Amador XF; Strauss DH; Yale SA; Gorman JM
    Schizophr Bull; 1991; 17(1):113-32. PubMed ID: 2047782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.